Elev8 Research Brief
Tirzepatide: Dual GIP/GLP-1 Receptor Research
An Elev8 Health editorial review of published scientific and regulatory literature.
Elev8 Health did not conduct the studies summarized below unless expressly stated otherwise. Research Briefs are educational summaries of third-party scientific literature and regulatory information.
Current Evidence Profile
Human Clinical Evidence
Strong for FDA-Approved Pharmaceutical Formulations
Elev8 Research Material FDA Approved
No
Development Status
Approved Product Exists
Human research is presented for scientific and educational context only. Elev8 Health does not recommend that its products be used for anything other than laboratory research purposes, and does not recommend human or veterinary use of any kind.
Introduction
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Unlike retatrutide, tirzepatide is the active ingredient in FDA-approved prescription products. The Elev8 research product, however, is not the FDA-approved pharmaceutical product and should not be represented as interchangeable with it.
Research Areas
Mechanisms
Dual incretin-receptor agonism is investigated for combined effects on glycemic regulation and appetite signaling.
Human Evidence
The SURMOUNT-1 Phase 3 trial enrolled more than 2,500 adults with overweight or obesity without diabetes and demonstrated substantial reductions in body weight compared with placebo. Later Phase 3 research also evaluated tirzepatide in people with obesity and moderate-to-severe obstructive sleep apnea.
Human research is presented for scientific and educational context only. Elev8 Health does not recommend that its products be used for anything other than laboratory research purposes, and does not recommend human or veterinary use of any kind.
Preclinical Evidence
Receptor pharmacology and preclinical metabolic research preceded the clinical program.
Limitations
FDA approval applies to labeled formulations and indications administered under medical supervision. Elev8 research material is not that product and is not represented as equivalent, bioequivalent or interchangeable.
Safety & Regulatory
Approved labeling exists for ZEPBOUND and related tirzepatide products. Elev8 research material is not FDA approved.
Conclusion
The tirzepatide literature is a clear example of formulation-specific evidence: robust human trials support approved pharmaceutical products, not research-use material.
Elev8 Research Editorial Team • Evidence reviewed: 2026-08-22